AJCP / Meeting AbstrActs and eosinophils. Immunohistochemical staining demonstrated positivity for IgG, IgG4, IgA, kappa and lambda light chains, CD3, CD10, CD15, CD20, CD79A, BCL-2, MUM-1, and CD138. A neu N stain disclosed focal, minimal neuronal loss while GFAP demonstrated background reactive astrocytes. The lesion showed positivity for EBV, which is consistent with current literature, but also for human herpesvirus 1 (HHV1) proven by polymerase chain reaction (PCR). This case is noteworthy for the rarity of presentation, diagnostic challenges and positivity for EBV and HHV1 by PCR.
Introduction: Angiosarcoma of the spleen is an uncommon condition, comprising only 2.7% of all angiosarcomas. It is common for splenic angiosarcoma to metastasize to other organs. The diagnosis of splenic angiosarcoma is made by either acute abdominal symptoms after splenic rupture or incidentally from radiologic surveillance. We report herein a case of splenic angiosarcoma with documented unique genomic mutations that have not been previously reported. Case Report: An 81-year-old man presented with thrombocytopenia and progressive splenomegaly over several years; a diagnosis of immune thrombocytopenia purpura was initially made. The patient subsequently developed sclerotic-blastic bone lesions with worsened splenomegaly. Bone marrow and bone biopsies revealed angiosarcoma, which was considered to be metastatic from the spleen based on imaging. He received multiple cycles of chemotherapy with minimal improvement. Eventually, the patient underwent splenectomy and the diagnosis of primary splenic angiosarcoma was made. Tissue sections showed a mitotically active cellular spindle cell neoplasm with pleomorphic nuclei, diffusely configured in anastomosing vasoformative channels. Zones of fibrosis, infarction, or active tumor necrosis comprised less than 5% of the splenic volume. Metastases to lymph nodes, peripancreatic fat and bone marrow were documented. Immunostains showed diffuse and strong immunoreactivity for CD31 and CD34, supporting a vascular origin. Molecular testing showed mutations in the following genes: ATRX, CDKN2A/B, EPHA3, MLL2, NOTCH2, and TET2. Conclusion: Primary splenic angiosarcoma is a rare entity with limited published molecular data. To our knowledge, the composite of genomic mutations outlined herein have not been previously reported in splenic angiosarcomas. CDKN2A/B has been reported in hepatic angiosarcomas. The molecular pathways that contribute to the development of appendiceal mucinous neoplasms have recently received additional attention. The most common identified mutations found in low-grade appendiceal mucinous neoplasm (LAMN) are in the KRAS and GNAS genes, which often are concomitantly mutated. KRAS and GNAS mutations coexist with some frequency in other entities, including pancreatic intraepithelial neoplasia (PanIN) and villous adenomas of the colorectum. Similarly, genetic alterations in the tumor suppressor gene cyclin dependent kinase inhibitor 2A (CDKN2A) have been implicated in PanIN progression and in colonic adenomas. CDKN2A gene mutation previously has been associated with hereditary forms of cutaneous melanoma, colorectal carcinoma, pancreatic adenocarcinoma, gastric carcinoma, epithelial ovarian carcinoma, prostate carcinoma, head and neck squamous cell carcinoma, and non-small cell lung carcinoma. The presence of CDKN2A mutation in precursor lesions in the colon and pancreas suggests there may be an association to LAMN, similar to the GNAS mutation association with LAMN, PanIN, and villous adenoma of the colon. To date, there are no descriptions of this potential association in the literature, and additional studies are needed. We present a case of an incidental LAMN in a 37-year-old patient with a strong family history of malignancy and a germline CDKN2A mutation who underwent a prophylactic subtotal colectomy for polyposis.
The Development of a Custom LIMS: An Introduction and Guide to Successful Implementation
Jeff Catalano, Gloria Cheang, Danielle Pancirer, Elyze Merzier, Yuewei Li, PhD, Hung Tran, Alexandros Sigaras; Weill Cornell Medicine, New York, NY The introduction and implementation of a laboratory information management system (LIMS) into an already operational clinical setting is a daunting challenge. There are ample and significant risks to consider when transitioning from one set of manual practices to a new and untested set of automated processes. But there are profuse benefits as well. A LIMS provides efficiency and reproducibility of clinical workflows, substantially reduces paperwork, and increases the bandwidth of clinical
